Clinical trial on the efficacy of two interventions for discontinuing long term benzodiazepine use in primary care

ISRCTN ISRCTN13024375
DOI https://doi.org/10.1186/ISRCTN13024375
Secondary identifying numbers PS09/00947
Submission date
17/06/2010
Registration date
27/07/2010
Last edited
18/02/2014
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Not provided at time of registration

Contact information

Dr Catalina Vicens
Scientific

C/ Matamusinos, 22 (Ponent-Son Serra-La Vileta)
Palma de Mallorca
07013
Spain

Email Cvicenscaldentey@ibsalut.caib.es

Study information

Study designMulticentre cluster randomised controlled three-arm parallel group trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)GP practice
Study typeOther
Participant information sheet Not available in web format, please contact Mr Alfonso Leiva Rus [aleiva@ibsalut.caib.es] to request a patient information sheet
Scientific titleA cluster randomised controlled trial on the efficacy of a structured educational intervention or minimal intervention versus usual care for discontinuing long term benzodiazepine use in primary care
Study acronymBENZORED
Study hypothesisAlthough short-term efficacy of benzodiazepines (BZD) is well established, long-term efficacy remains controversial and long term use is usually not recomended because of potential adverse effects and the risks of tolerance and dependence, increased risk of hip fractures, motor vehicle accidents and memory impairments. Most guidelines recommend restricting their use to short periods only, but nevertheless they are widely prescribed.

Objective:
To evaluate the efficacy of a structured educative intervention (SEI) and of a minimal intervention (MI) performed by the family General Practitioner (GP) to discontinue long term BZD use, compared to usual care. To evaluate the safety of these interventions in anxiety and depression symptoms, sleep quality and alcohol consumption.

Hypotheses:
1. In primary care patients on long-term benzodizapine, a structured educational intervention results in a cessation rate of 40% after one year, compared to 25% with minimal intervention and less than 10% with usual care
2. The interventions proposed (EI and MI) do not induce more symptoms of anxiety and depression or affect quality of sleep and alcohol consumption compared to the control group
Ethics approval(s)The Ethics Committee of the Balearic Islands (Comité Ético Investigación Clínica [CEIC])approved on the 29th April 2009
ConditionBenzodiazepine use, reduction and withdrawal
InterventionPatients were randomised to one of three groups, comparing two strategies for the reduction of chronic bendzodizepine and a control group:
1. Structured educational intervention: 1 educational interview (20 - 25 minutes) which addresses some specific aspects of chronic use of benzodiazepines with a pattern of gradual dose reduction of benzodiazepine and 4 - 6 subsequent follow-up visits to control the gradually descending dose
2. Minimal intervention: 1 educational interview (20 - 25 minutes) which addresses some specific aspects of chronic use of benzodiazepines with written information on the pattern of gradually reducing the dosage of benzodiazepine
3. Control group: usual clinical practice, no intervention visits

There will be follow up visits at 6 and 12 months, of 35 minutes duration.
Intervention typeOther
Primary outcome measureBenzodiazepine use at 12 months
Secondary outcome measures1. Anxiety and Depression Scale
2. Quality of Sleep Scale
3. Alcohol consumption

Outcomes will be measured at baseline, 6 and 12 months.
Overall study start date15/07/2010
Overall study end date15/10/2012

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsTotal sample size is 495 patients from primary health care centres in three Spanish regions
Participant inclusion criteria1. Patients between 18 and 80 years
2. Recorded history of benzodiazepine consumption or an analogue at least 5 times a week for at least six months
3. A minimum of 6 months prescription of a benzodiazepine or similar
Participant exclusion criteria1. Patients with severe anxiety or depressive disorder, psychotic disorder, severe personality disorder, and/or psychiatric monitoring
2. Patients with cognitive impairment, terminal illness or serious medical conditions, illegal drug use or abuse alcohol, inability to sign informed consent
3. Institutionalised patients
4. Patients with exacerbation of symptoms of anxiety/depression whose doctor considers that the withdrawal of a benzodiazepine can be harmful at this time
5. Patients with limited capacity for understanding
6. Patients that have participated in a clinical research study during the last 3 months
Recruitment start date15/07/2010
Recruitment end date15/10/2012

Locations

Countries of recruitment

  • Spain

Study participating centre

C/ Matamusinos, 22 (Ponent-Son Serra-La Vileta)
Palma de Mallorca
07013
Spain

Sponsor information

Health Service of the Balearic Islands (Servei de Salut de les Illes Balears [IB-salut]) (Spain)
Government

Mallorca Primary Care Management
C/ Reina Esclaramunda nº 9
Palma de Mallorca
07003
Spain

Phone +34 (0)971 175883
Email aleiva@ibsalut.caib.es
ROR logo "ROR" https://ror.org/00d9y8h06

Funders

Funder type

Government

Health Research Fund (Fondo de Investigaciones Sanitarias [FIS]) (Spain)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 20/04/2011 Yes No
Results article results 01/06/2014 Yes No